Pluri (NASDAQ:PLUR) Releases Quarterly Earnings Results

Pluri (NASDAQ:PLUR) released its earnings results on Wednesday. The company reported ($0.65) EPS for the quarter, Zacks reports. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 1,701.19%.The company had revenue of $0.32 million for the quarter.

Pluri Price Performance

Shares of NASDAQ PLUR traded down $0.32 during mid-day trading on Friday, reaching $3.86. The company’s stock had a trading volume of 113,743 shares, compared to its average volume of 21,078. The stock has a 50-day moving average of $4.32 and a two-hundred day moving average of $4.72. The company has a debt-to-equity ratio of 51.65, a quick ratio of 0.68 and a current ratio of 0.68. The stock has a market capitalization of $31.48 million, a P/E ratio of -0.75 and a beta of 0.63. Pluri has a 1-year low of $3.22 and a 1-year high of $7.13.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pluri in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Trading of Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC bought a new position in Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors and hedge funds.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.